P140 International Patent Filing Update

AI SummaryClose X

ImmuPharma PLC has filed an international Patent Cooperation Treaty (PCT) application for its P140 precision medicine approach in autoimmune disease, specifically targeting patients with the Type M immune profile. This filing builds upon a previous UK priority patent application and incorporates additional experimental data generated during the priority period, strengthening the scientific basis for the P140 and Type M approach. The PCT application will now proceed through an international search and publication phase, allowing ImmuPharma to pursue patent protection in selected jurisdictions. The company continues to advance discussions for a value-enhancing commercial deal for P140, which remains a core strategic asset.

Disclaimer*

Companies

Immupharma (IMM)
UK 100

Latest directors dealings